文献速递食管与纵隔外科

手术与T4a期食管腺癌生存获益相关:一项全国性分析

Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis.
PubMed 文献 · Ann Thorac Surg · 2019-07-26

基于美国国家癌症数据库2010-2015年182例cT4aN0-3M0食管腺癌患者,比较手术(含围手术期治疗)与根治性放化疗的生存差异。多因素分析显示手术组死亡风险显著低于放化疗组(校正HR 0.32,95%CI 0.21-0.50),倾向性匹配分析结果一致(HR 0.26,95%CI 0.16-0.43)。

要点

  • cT4aN0-3M0食管腺癌手术组较根治性放化疗组生存显著改善。
  • 多因素校正后手术与死亡风险降低相关(HR 0.32,95%CI 0.21-0.50)。
  • 倾向性匹配分析验证手术组生存获益(HR 0.26,95%CI 0.16-0.43)。

核心结论

  • 在cT4aN0-3M0食管腺癌患者中,手术(含围手术期治疗)与根治性放化疗相比与改善的生存结局相关。
  • 对于医学上适合的患者,应考虑手术治疗cT4aN0-3M0食管腺癌。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库(National Cancer Database)2010-2015年数据。
  • 纳入182例临床T4aN0-3M0食管腺癌患者,按接受手术(伴或不伴围手术期治疗)或根治性同步放化疗分组。
  • 排除接受不完整根治性治疗或缺失生存信息的患者。
  • 采用Kaplan-Meier法和Cox比例风险分析评估总生存,并进行1:1倾向性评分匹配分析。

主要发现

  • 182例患者中,85例(47%)接受食管切除术,97例(53%)接受放化疗。
  • 手术组中79例(93%)接受了围手术期化疗。
  • 未校正和多因素分析显示手术较根治性放化疗与显著生存获益相关(校正HR 0.32;95%CI 0.21-0.50)。
  • 63对患者的1:1倾向性评分匹配分析显示手术较单纯放化疗有显著总生存获益(HR 0.26;95%CI 0.16-0.43)。

关键数值与推荐

  • NCCN指南推荐考虑对临床T4a食管腺癌进行手术。
  • 研究纳入标准:2010-2015年临床T4aN0-3M0食管腺癌。
  • 手术组93%(79/85)接受围手术期化疗。

临床怎么用

  • 对于医学上适合的cT4aN0-3M0食管腺癌患者,手术应作为考虑的治疗选择。
  • 手术通常联合围手术期化疗,多数手术患者(93%)接受了围手术期化疗。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The National Comprehensive Cancer Network guidelines recommend consideration of surgery for clinical T4a esophageal adenocarcinoma. There are limited data on the outcomes of patients with T4a adenocarcinoma treated with surgery vs definitive chemoradiation, however. METHODS: The National Cancer Database was used to identify patients from 2010-2015 with clinical T4aN0-3M0 esophageal adenocarcinoma, and grouped by receipt of surgery (with or without perioperative therapy) or definitive, concurrent chemoradiation. Patients receiving incomplete definitive therapy or with missing survival information were excluded. Overall survival was evaluated with Kaplan-Meier and Cox proportional hazard analyses. RESULTS: Of 182 patients in the study, 85 (47%) underwent esophagectomy and 97 (53%) underwent chemoradiation. In the surgery cohort, 79 patients (93%) received perioperative chemotherapy. Unadjusted and multivariable analyses demonstrated a significant survival benefit associated with surgery compared with definitive chemoradiotherapy (adjusted hazard ratio 0.32; 95% confidence interval 0.21, 0.50). A 1:1 propensity score-matched analysis of 63 patient pairs also revealed a significant overall survival benefit with surgery compared with chemoradiotherapy alone (hazard ratio 0.26; 95% confidence interval 0.16, 0.43). CONCLUSIONS: In this national analysis, surgery for cT4a esophageal adenocarcinoma was associated with improved outcomes when compared with definitive chemoradiation. Surgery should be considered for medically fit patients with cT4aN0-3M0 esophageal adenocarcinoma.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Raman V, Jawitz OK, Voigt SL, et al. Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis. Ann Thorac Surg. 2019. PMID: 31356800. doi:10.1016/j.athoracsur.2019.05.091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。